000			02045nam a2200289Ia 4500
003			MX-MdCICY
005			20250625162457.0
040			_cCICY
090			_aB-20880
245	1	0	_aZika virus: Antiviral immune response, inflammation, and cardiotonic steroids as antiviral agents
490	0		_vInternational ImmunoPharmacology, 127, p.111368, 2024
520	3		_aZika virus (ZIKV)is a mosquito-borne virus first reported from humans in Nigeria in 1954. The first outbreak occurred in Micronesia followed by an outbreak in French Polynesia and another in Brazil when the virus was associated with numerous cases of severe neurological manifestations such as Guillain-Barre syndrome in adults and congenital zika syndrome in fetuses, particularly congenital microcephaly. Innate immunity is the first line of defense against ZIKV through triggering an antiviral immune response. Along with innate immune responses, a sufficient balance between anti- and pro-inflammatory cytokines and the amount of these cytokines are triggered to enhance the antiviral responses. Here, we reviewed the complex interplay between the mediators and signal pathways that coordinate antiviral immune response and inflammation as a key to understanding the development of the underlying diseases triggered by ZIKV. In addition, we summarize current and new therapeutic strategies for ZIKV infection, highlighting cardiotonic steroids as antiviral drugs for the development of this agent.
650	1	4	_aARBOVIRUS
650	1	4	_aCYTOKINES
650	1	4	_aIMMUNE RESPONSE
650	1	4	_aOUABAIN
650	1	4	_aZIKV
700	1	2	_aDe Sales-Neto, J. M.
700	1	2	_aCarvalho, D. C. M.
700	1	2	_aMagalhães, D. W. A.
700	1	2	_aMedeiros, A. B. A.
700	1	2	_aSoares, M. M.
700	1	2	_aRodrigues-Mascarenhas, S.
856	4	0	_uhttps://drive.google.com/file/d/1DSSVv50bjduvfFh-Rd7NmcyZDUSlRhiC/view?usp=drivesdk _zPara ver el documento ingresa a Google con tu cuenta: @cicy.edu.mx
942			_2Loc _cREF1
008			250602s9999 xx |||||s2 |||| ||und|d
999			_c54960 _d54960